Axovant Sciences Ltd

Most Recent

  • uploads///Axovant clinical pipeline
    Company & Industry Overviews

    Investors Still Excited about Axovant

    Axovant is focusing on gene therapy candidates AXO-Lenti-PD and AXO-AAV-OPMD.

    By Kenneth Smith
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///medicine _
    Company & Industry Overviews

    Axovant and Benitec Biopharma Up on Gene Therapy Development Deal

    Today, Axovant Sciences (AXON) registered a stock price rise of over 3.0%, and Australian firm Benitec Biopharma’s (BNTC) stock rose ~57.0%.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///Axovant ana reco
    Company & Industry Overviews

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    A Look at Axovant Sciences’ Therapy for Parkinson’s Disease

    Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease).

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    Why Axovant Sciences Stock Is Soaring

    Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80.

    By Margaret Patrick
  • uploads///Fei
    Company & Industry Overviews

    Why Axovant Sciences Stock Rose in Week Ended June 8

    On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.

    By Daniel Collins
  • uploads///dna _
    Healthcare

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.